Table 1.
Demographic and Cancer Characteristics for the Study Population
| All | Polypharmacy (≥9 medications) | p-value* | ||
|---|---|---|---|---|
| No | Yes | |||
| Total Patients | N= 357 | N= 270 | N= 87 | |
| Age, mean (SD) | 70.1 (7.3) | 69.9 (7.4) | 70.6 (7.1) | 0.3847 |
| Age, n (%) | ||||
| 60-64 | 97 (27.2) | 78 (28.9) | 19 (21.8) | 0.6901 |
| 65-69 | 84 (23.5) | 63 (23.3) | 21 (24.1) | |
| 70-74 | 78 (21.8) | 56 (20.7) | 22 (25.3) | |
| 75-79 | 54 (15.1) | 39 (14.4) | 15 (17.2) | |
| 80+ | 44 (12.3) | 34 (12.6) | 10 (11.5) | |
| Sex, n (%) | ||||
| male | 202 (56.6) | 160 (59.3) | 42 (48.3) | 0.0723 |
| female | 155 (43.4) | 110 (40.7) | 45 (51.7) | |
| Race, n (%) | ||||
| white | 268 (75.1) | 201 (74.4) | 67 (77.0) | 0.8828 |
| Black | 84 (23.5) | 65 (24.1) | 19 (21.8) | |
| Ethnicity, n (%) | ||||
| Hispanic | 8 (2.2) | 7 (2.6) | 1 (1.1) | 0.4290 |
| Educational Level, n (%) | ||||
| less than high school | 63 (17.6) | 47 (17.4) | 16 (18.4) | 0.3177 |
| high school graduate | 97 (27.2) | 71 (26.3) | 26 (29.9) | |
| some college | 64 (17.9) | 47 (17.4) | 17 (19.5) | |
| associate / bachelor’s degree | 100 (28.0) | 75 (27.8) | 25 (28.7) | |
| advanced degree | 33 (9.2) | 30 (11.1) | 3 (3.4) | |
| Employment, n (%) | ||||
| retired | 216 (60.5) | 162 (60.0) | 54 (62.1) | 0.0211 |
| disabled | 47 (13.2) | 28 (10.4) | 19 (21.8) | |
| part-time (<32hr/week) | 10 (2.8) | 9 (3.3) | 1 (1.1) | |
| full-time (>32hr/week) | 38 (10.6) | 33 (12.2) | 5 (5.7) | |
| other | 46 (2.9) | 38 (14.1) | 8 (9.2) | |
| Marital Status, n (%) | ||||
| single | 26 (7.3) | 18 (6.7) | 8 (9.2) | 0.5857 |
| widowed / divorced | 103 (28.9) | 76 (28.1) | 27 (31.0) | |
| married | 228 (63.9) | 176 (65.2) | 52 (59.8) | |
| Cancer Type, n (%) | ||||
| Colorectal | 120 (33.6) | 87 (32.2) | 33 (37.9) | 0.6045 |
| Pancreatic | 88 (24.6) | 66 (24.4) | 22 (25.3) | |
| Hepatobiliary | 58 (16.2) | 43 (15.9) | 15 (17.2) | |
| Gastroesophageal | 39 (10.9) | 33 (12.2) | 6 (6.9) | |
| Other (NEC, GIST, Anal) | 52 (14.6) | 41 (15.2) | 11 (12.6) | |
| Cancer Stage, n (%) | ||||
| 0-II | 106 (29.7) | 75 (27.8) | 31 (35.6) | 0.2665 |
| III | 93 (26.1) | 75 (27.8) | 18 (20.7) | |
| IV | 158 (44.3) | 120 (44.4) | 38 (43.7) | |
*
based on comparison between patients with polypharmacy and patients without polypharmacy